Source: Algernon Pharmaceuticals.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon Pharmaceuticals (AGN) has appointed Mr. James Kinley as the Chief Financial Officer replacing Mike Sadhra
  • Mr. Kinley is a Certified Professional Accountant with over 15 years of experience in building, leading and advising corporations
  • Mr. Kinley spent nearly 10 years as the CFO for Medicure Inc.
  • Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.10 per share

Algernon Pharmaceuticals (AGN) has appointed Mr. James Kinley as the Chief Financial Officer (CFO), effective December 1, 2021.

Mr. Kinley will report to Algernon’s Chief Executive Officer Christopher J. Moreau.

Mr. Kinley is a Certified Professional Accountant with over 15 years of experience in building, leading, and advising corporations through their day-to-day operations as well as on complex restructurings, mergers, acquisitions, and capital markets transactions. He has had success in structuring and negotiating favourable terms with commercial and investment banks.

James was previously the CFO for Medicure Inc. (TSXV:MPH), a Canadian pharmaceutical company, a position he held for nearly 10 years.

Christopher J. Moreau CEO of Algernon Pharmaceuticals commented on the appointment.

“James Kinley brings significant functional expertise and technical knowledge to the Company in all aspects of corporate finance, financial planning and accounting. We have been developing a significant pipeline of research programs and we look forward to James joining the team as we work to aggressively execute our exciting business plan.”

The company would like to thank departing CFO Mike Sadhra for his many years of service and wishes him the best in his future pursuits.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.10 per share.

More From The Market Herald

" LevelJump Healthcare (TSXV:JUMP) announces $2.5M private placement

LevelJump Healthcare (JUMP) will be conducting a non-brokered private placement financing for gross proceeds of up to $2,500,000.

" Leveljump Healthcare (TSXV:JUMP) provides corporate update

Leveljump Healthcare (JUMP) has agreed to acquire an additional minority interest in Real Time Medical (RTM), Shaw Lens, and Shaw Vision.

" PharmaDrug (CSE:PHRX) engages Octagon Media for an investor marketing campaign

PharmaDrug Inc. (PHRX) has engaged Octagon Media Corp to assist in a digital media advertising campaign coupled with an investor marketing program.

" Bloom Health Partners Inc. (CSE:BLMH) receives DTC eligibility

Common shares of Bloom Health Partners (BLMH) are now eligible for electronic clearing and settlement through the Depository Trust Company.